PIONEERING NANO-BIOTECHNOLOGY COMPANY. WITH OVER 20 YEARS RESEARCHING AND DEVELOPING OUR PATENT-PENDING NANOSPHERE DELIVERY SYSTEM™.
PATENTED NANOSPHERE DELIVERY TECHNOLOGY™ INCREASES THE BIOAVAILABILITY AND BIOACTIVITY OF CANNABINOIDS.
NANOSPHERE HEALTH IS THE FIRST AND ONLY COMPANY TO NANO-SIZE AND ENCAPSULATE CANNABINOIDS, DRAMATICALLY CHANGING THE INDUSTRY.
Kate S. Wells
CMO
NanoSphere Health Sciences, Inc.
d: 720.528.4437 | c: 303.324.7358
www.nanospherehealth.com
CSE: NSHS
PIONEERING NANO-BIOTECHNOLOGY COMPANY. WITH OVER 20 YEARS RESEARCHING AND DEVELOPING OUR PATENT-PENDING NANOSPHERE DELIVERY SYSTEM™.
PATENTED NANOSPHERE DELIVERY TECHNOLOGY™ INCREASES THE BIOAVAILABILITY AND BIOACTIVITY OF CANNABINOIDS.
NANOSPHERE HEALTH IS THE FIRST AND ONLY COMPANY TO NANO-SIZE AND ENCAPSULATE CANNABINOIDS, DRAMATICALLY CHANGING THE INDUSTRY.
NSHSF: Yes, for our expanding opportunities in cannabis and other divisions. We will be doing another raise in the $10-15M range.
CI: Would your company be considered less of a risk versus industry peers, due to the fact your revenue model doesn’t rely solely on the cannabis industry?
NSHSF: Absolutely. We have completed years of R&D and our now at a pivotal point of commercializing our revolutionary technology to a broad range of industries. We are undoubtedly changing the cannabis industry by laying the foundations of effective delivery for the first time. We promise to always provide precise dosages, high bioavailability, rapid action and effective delivery of cannabis into systemic circulation. NanoSphere’s industry-first technology is the disruptor that will be marijuana a credible and legitimate medical tool.
Beyond cannabis, our three additional divisions of pharmaceuticals, nutraceuticals and cosmeceuticals have the potential to reshape and reimage their respective industries using this technology. Combined, these industries are valued at an estimated $900 billion nationwide and we plan to improve non-invasive delivery across them all. In these sectors, we will create multiple product lines and variations of applications for the NanoSphere Delivery System™, starting with our over-the-counter, NSAIDS and nutraceutical division which is expected to launch products in 2019. Our patent is the bedrock of all of these opportunities in front of us.
CI: Why should investors invest in NanoSphere Health Sciences?
NSHSF: We recently completed a reverse merger into a Canadian public shell, and NanoSphere is now public and on the Canadian Securities Exchange. We did that partially because of the market up there being much more receptive to it. Secondarily we also have an agreement ready to be put in place with a Canadian producer, which will make our product available across Canada. We are also trading on the OTC, enabling some people in the US to be able to access the stock and be participants as investors.
The goal of the company is to build up our licensing of our products with producers in different legal jurisdictions. We generate our revenue based off of them selling a product that’s made with our technology. We don’t actually grow or harvest cannabis; we simply help convert the oil into a product that is much more acceptable in the marketplace than what’s currently out there, certainly from a physician’s perspective, because of the way it’s delivered and the medical aspects of it.
We’re just breaking into the industry, so the opportunity for growth is quite large. You can trust in us because we actually back up what we’re saying with scientific, clinically proven data. Our NanoSphere team is made up of experienced business people that know how to market, drive companies, and build brands. So not only do we have the science down, but we also have the business side down. I think that’s a real reason that investors can trust with us. Plus, the value of the IP alone is of significant worth.
153